The Zepbound Shortage Is Over — Here's What to Expect if You've Been Buying from a Compounding Pharmacy
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
Weight-loss drugs take over year of 2024: Bloomberg
Seemingly overnight, millions of people were taking the medicines, known as GLP-1s, while blockbuster drugs like Ozempic, Wegovy, Mounjaro, and Zepbound brought in billions for pharma companies, and a ...
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...
'What a difference a year makes': Stocks in this sector are set to surge in 2025 after a disappointing year, Citi says
Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight ...
KSJB AM3h
Which State Medicaid Programs Cover GLP-1s for Weight Loss & How Much Are They Spending?
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
Hastings Tribune4h
Kansas Medicaid Spend on GLP-1s for Obesity up 97% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
24/7 Wall St5h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...